Business / Finance

RSS

Synexus wins first contract to conduct ophthalmology studies

Synexus, the world's largest company responsible for the recruitment and running of clinical trials, has won its first contract to conduct ophthalmology studies.

From AES - Accelerated Enrollment Solutions 7 Feb 2011

Pfizer enters definitive agreement to purchase Ferrosan's consumer healthcare business

Pfizer Inc. today announced that it has entered into a definitive agreement to purchase Ferrosan's consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

7 Feb 2011

Cegedim's consolidated fourth quarter 2010 revenues increase 10.1%

Cegedim, a global technology and services company specializing in the healthcare field, generated consolidated Q4 2010 revenues of €266.5 million, a 10.1% increase on a reported basis and up 2.9% like for like. Revenue growth was stronger than the Group had expected, due in large part to an excellent December in every business sector.

5 Feb 2011

General Cannabis subsidiaries show expected success, growth in January 2011

The General Cannabis, Inc. subsidiaries are already showing expected success and growth in the year's first quarter.

5 Feb 2011

Maxygen distributes Codexis's shares to its stockholders for U.S. Federal income tax purposes

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its distributions of Codexis, Inc. common stock and cash in December 2010 will be classified as a return of capital to its stockholders for U.S. Federal income tax purposes.

5 Feb 2011

Pharmacyclics second quarter non-GAAP net loss increases to $6.1 million

Pharmacyclics, Inc. today reported recent developments and financial results for its fiscal second quarter that ended December 31, 2010.

5 Feb 2011

MetaMorphix announces sale under Chapter 11

MetaMorphix, Inc., an animal biotechnology company, announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. The Company also announced that American MedTech Advisors has been retained to assist in the sale of the Company.

5 Feb 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.

5 Feb 2011

HCR to pay off existing term loan and revolving credit facilities

HCR ManorCare, Inc. has announced its intention to refinance its term loan and revolving credit facilities. The new term loan is for $400 million, and the revolving credit agreement is for $150 million.

5 Feb 2011

Lotus adds two additional stories to new Beijing headquarters building

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced that it will add two additional stories to its new headquarters building in Chaoyang District, Beijing, which is currently under construction and is scheduled to be completed in the second quarter of 2011.

5 Feb 2011

NYSE Amex accepts Palatin's exchange listing compliance plan

Palatin Technologies, Inc. reported that its exchange listing compliance plan has been accepted by the NYSE Amex. Palatin has been granted an extension until May 26, 2011 to regain compliance with stockholders' equity requirements under Section 1003(a)(iii) of the NYSE Amex Company Guide and until February 28, 2011 to regain compliance with financial condition continued listing requirements under Section 1003(a)(iv).

5 Feb 2011

The Female Health Company first quarter FY2011 net revenues decrease 33%

The Female Health Company, which manufactures and markets the FC2 Female Condom, today reported its operating results for the first quarter of FY2011.

5 Feb 2011

Continucare second quarter total revenue increases 7% to $80.3 million

Continucare Corporation today reported record financial results for its second quarter of fiscal 2011.

5 Feb 2011

Onset Therapeutics announces corporate name change to Onset Dermatologics

Onset Therapeutics, a PreCision Dermatology company and a leader in the development and commercialization of novel, prescription products for the treatment of skin disorders, today announced that it has changed its corporate name to Onset Dermatologics.

5 Feb 2011

Endocyte prices initial public offering

Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates, announced today the pricing of its initial public offering of 12,500,000 shares of its common stock.

5 Feb 2011

Partek signs distribution agreement with Life Technologies

Partek Incorporated, a global leader in bioinformatics software, announced today the signing of a distribution agreement with Life Technologies Corporation, a provider of next-generation DNA sequencing technology. The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies' next-generation sequencing devices.

5 Feb 2011

Microsulis' Microwave Endometrial Ablation platform sold to Hologic

Microsulis Medical Limited announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From Hologic, Inc. 5 Feb 2011

ArtVentive announces $10,000,000 USD agreement with European financial group

ArtVentive Medical Group, announced today a ten million dollar financing agreement with a European financial group. A firm commitment for the first tranche of $1,950,000 is at $.90 per share with the remainder of the financing to be priced at not less than $.90 per share.

5 Feb 2011

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2011 first quarter, ended December 31, 2010, diluted earnings per share were $0.57, a 10 percent increase. Revenue in the quarter was a record $19.9 billion, up 3 percent.

4 Feb 2011

Savient closes sale of $230M 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

4 Feb 2011